Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06557356 | A Study of LY3532226 in Participants With Obesity | PHASE1 | COMPLETED | 132 | — | — | Aug 16, 2024 | Dec 12, 2025 | Jan 20, 2026 | 4 | United States, Singapore |
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3532226 (Part A) | EXPERIMENTAL | LY3532226 administered subcutaneously (SC) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part B) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part C) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part C) | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3532226 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²) * Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screenin...